Aligos Therapeutics Files 8-K on Financials

Ticker: ALGS · Form: 8-K · Filed: May 6, 2025 · CIK: 1799448

Aligos Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAligos Therapeutics, Inc. (ALGS)
Form Type8-K
Filed DateMay 6, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, sec-filing

Related Tickers: ALGS

TL;DR

ALGS filed an 8-K on May 6th, 2025, updating on financials. No specific numbers yet.

AI Summary

Aligos Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as providing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.

Why It Matters

This filing indicates Aligos Therapeutics is providing updates on its financial status and operational results to the SEC, which is important for investors to monitor the company's performance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial information and does not contain any immediate negative news or significant changes.

Key Players & Entities

  • Aligos Therapeutics, Inc. (company) — Registrant
  • May 6, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • South San Francisco, California (location) — Principal Executive Offices

FAQ

What specific financial results are being reported by Aligos Therapeutics in this 8-K?

The provided text of the 8-K filing does not contain specific financial figures or details about the results of operations.

What is the primary purpose of this 8-K filing for Aligos Therapeutics?

The primary purpose is to report on the company's Results of Operations and Financial Condition, and to provide Financial Statements and Exhibits.

When was this 8-K filing submitted to the SEC?

The filing was made on May 6, 2025.

What is Aligos Therapeutics' principal executive office address?

The principal executive offices are located at One Corporate Dr., 2nd Floor, South San Francisco, California 94080.

What is the SIC code for Aligos Therapeutics?

The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Aligos Therapeutics, Inc. (ALGS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.